{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:54:42Z","timestamp":1791021282449,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["A28724"],"award-info":[{"award-number":["A28724"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["RRCOER-Jun24\/100006"],"award-info":[{"award-number":["RRCOER-Jun24\/100006"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CSDG-20-013-01-CCE"],"award-info":[{"award-number":["CSDG-20-013-01-CCE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:39:30Z","timestamp":1790890770000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-5522","authenticated-orcid":false,"given":"Soumyajit","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmineh","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Mack","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff M.","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Incrocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Heemsbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"de Pos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"de Reijke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdenour","family":"Nabid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee L.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kekoa","family":"Taparra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sanguineti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Zapatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4836-8483","authenticated-orcid":false,"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.09.007_b0005","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines in Prostate Cancer, v.2.2026. NCCN guidelines panel disclosures. National Comprehensive Cancer Network Web site. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459."},{"key":"10.1016\/j.euo.2026.09.007_b0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med. DC: T W"},{"key":"10.1016\/j.euo.2026.09.007_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35069","article-title":"Conditional risks of biochemical failure and prostate cancer\u2013specific death in patients undergoing external beam radiotherapy: a secondary analysis of 2 randomized clinical trials","volume":"6","author":"Alexander","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.09.007_b0020","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0025","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.juro.2007.01.137","article-title":"Prostate specific antigen recurrence after definitive therapy","volume":"177","author":"Freedland","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0030","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part II: Recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: Risk stratification, shared decision making, and care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0040","article-title":"Natural history and risk stratification of biochemically recurrent prostate cancer following definitive radiation therapy","volume":"11","author":"Riviere","year":"2026","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.09.007_b0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0055","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0240","doi-asserted-by":"crossref","unstructured":"Prentice RL, Kalbfleisch JD, Hazard rate models with covariates. Biometrics 1979; 35(1), Perspectives in Biometry (Mar., 1979), pp. 25\u201339.","DOI":"10.2307\/2529934"},{"key":"10.1016\/j.euo.2026.09.007_b0060","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/sim.5665","article-title":"Dynamic prediction by landmarking in competing risks","volume":"32","author":"Nicolaie","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2026.09.007_b0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ijc.34923","article-title":"Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: a population-based study in Italy","volume":"155","author":"Dal Maso","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2026.09.007_b0070","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/ije\/dyaa128","article-title":"Cancer cure for 32 cancer types: results from the EUROCARE-5 study","volume":"49","author":"Dal Maso","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.euo.2026.09.007_b0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clon.2021.11.009","article-title":"Defining biochemical cure after low dose rate prostate brachytherapy: external validation of 4-year prostate-specific antigen nadir as a predictor of 10- and 15-year disease-free survival","volume":"34","author":"Noble","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.euo.2026.09.007_b0080","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0085","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.19.01904","article-title":"Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a Phase III randomized controlled trial","volume":"38","author":"Malone","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0090","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0095","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a Phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0100","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.09.007_b0110","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ijrobp.2009.12.039","article-title":"Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96\u201310 Trial)","volume":"79","author":"Al-Mamgani","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.09.007_b0115","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.6004\/jnccn.2021.7065","article-title":"Metastasis and mortality in men with low- and intermediate-risk prostate cancer on active surveillance","volume":"20","author":"Courtney","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2026.09.007_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15083","article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG 9408 randomized clinical trial","volume":"3","author":"Zumsteg","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.09.007_b0145","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.euo.2026.09.007_b0150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/hematology.2024000654","article-title":"In pursuit of a functional cure for follicular lymphoma","volume":"2024","author":"Trotman","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.euo.2026.09.007_b0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2021.09.037","article-title":"Prostate cancer dormancy and recurrence","volume":"524","author":"Cackowski","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.euo.2026.09.007_b0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00109-015-1353-4","article-title":"The biology and clinical implications of prostate cancer dormancy and metastasis","volume":"94","author":"Morrissey","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.euo.2026.09.007_b0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/JU.0000000000001036","article-title":"Competing risks of mortality among men with biochemical recurrence after radical prostatectomy","volume":"204","author":"Daskivich","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2022.40.6_suppl.282","article-title":"Disease progression and competing mortality for men undergoing active surveillance for low-risk prostate cancer","volume":"40","author":"Guram","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0175","article-title":"Major patterns of cancer cure: clinical implications","volume":"28","author":"Tralongo","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.euo.2026.09.007_b0180","doi-asserted-by":"crossref","first-page":"493.e1","DOI":"10.1016\/j.urolonc.2020.12.004","article-title":"Pathology grade influences competing mortality risks in elderly men with prostate cancer","volume":"39","author":"Alam","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0185","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.18.00154","article-title":"Time interval to biochemical failure as a surrogate end point in locally advanced prostate cancer: analysis of randomized trial NRG\/RTOG 9202","volume":"37","author":"Dignam","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0195","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ijrobp.2023.02.022","article-title":"A personalized clinical dynamic prediction model to characterize prognosis for patients with localized prostate cancer: analysis of the CHHiP Phase 3 trial","volume":"116","author":"Parr","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.09.007_b0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0205","article-title":"Prostate cancer risk stratification in NRG oncology Phase III randomized trials using multimodal deep learning with digital histopathology","volume":"8","author":"Tward","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (Leviathan)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2021.04.035","article-title":"Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer","volume":"80","author":"Philipson","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0220","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO-25-00274","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: 10-year outcomes of the FLAME trial","volume":"43","author":"Menne Guricov\u00e1","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.007_b0225","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.007_b0230","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/rg.2019180079","article-title":"Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread","volume":"39","author":"Barbosa","year":"2019","journal-title":"Radiographics"},{"key":"10.1016\/j.euo.2026.09.007_b0235","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.euo.2025.08.005","article-title":"Stage migration on prostate-specific membrane antigen positron emission tomography\/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: results from the Phase 2\/3 THUNDER trial","volume":"8","author":"Kleiburg","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:09:06Z","timestamp":1791018546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S2588931126002531"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR)","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}